Total Funding
47
54
Total FundingGrant raised
Growth Score
-9 pts
Heat Score
3 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
76490
GeneVentiv Therapeutics is a pre-clinical gene therapy company focused on blood diseases and disorders.
About the Company
GeneVentiv Therapeutics is a pre-clinical gene therapy company focused on blood diseases and disorders. With or without inhibitors, its flagship program, GENV-HEM, is the first universal gene therapy treatment for hemophilias A and B. The National Hemophilia Foundation has written a letter of support for GENV-HEM and the FDA has designated it as an
orphan drug. A further gene therapy is being developed by GeneVentiv for Hemophilia Arthropathy, a degenerative joint disease that affects about 50% of hemophilia patients.
